Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
In a report released yesterday, Graham Parry from Bank of America Securities maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF110.00. Graham Parry has ...
A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...